Mitomycin-c lipidic prodrug

Mitomycin-c lipidic prodrug (MLP) is a rationally designed lipid-based derivative of the cytotoxic agent mitomycin C (MMC), formulated for encapsulation in liposomes. The most clinically advanced formulation is Promitil, a pegylated liposomal version developed to improve delivery and reduce systemic toxicity. Upon administration, the MLP remains stable within circulating liposomes until it reaches tumor tissue, where reducing agents abundant in the tumor microenvironment cleave the thiol-sensitive linker and release active MMC locally[1][3][5]. Released MMC acts as an alkylating agent that generates oxygen radicals and forms interstrand DNA cross-links, thereby inhibiting DNA synthesis and inducing cell death[1]. This targeted release reduces exposure to healthy tissues and improves tolerability compared to free MMC. Promitil has demonstrated antitumor activity—including against multidrug-resistant cancers—and acts as a radiosensitizer with reduced toxicity in preclinical models and early clinical trials[2][5][8]. The primary indication under investigation is cancer therapy.

Brand names

Promitil

Other names

pegylated liposomal mitomycin C lipid-based prodrugmitomycin C lipidic prodrugpegylated liposomal MMC prodrug